CN116287190B - Polymorphic site combinations, kits and detection systems for evaluating the efficacy of ARB drugs - Google Patents

Abstract

The invention discloses a polymorphic locus combination for evaluating the curative effect of ARB drugs, which comprises the following steps: the rs6749447 locus, the rs10737062 locus, the rs10752271 locus and the rs3814995 locus for evaluating the efficacy of losartan; the rs1367117 site for evaluating the efficacy of losartan; the rs5443 locus, the rs1983023 locus and the rs2008584 locus are used for evaluating the curative effect of telmisartan; polymorphic site rs1275988 for assessing candesartan efficacy. A kit for evaluating the curative effect of ARB drugs comprises a primer group for identifying polymorphic sites. A detection system for evaluating the curative effect of ARB drugs. The invention has the beneficial effects of early identifying the benefited crowd using a specific ARB drug and effectively reducing the blood pressure of the patient.

Description

Polymorphic site combinations, kits and detection systems for evaluating the efficacy of ARB drugs

Technical field

The present invention relates to the fields of medicine and biotechnology. More specifically, the present invention relates to a polymorphic site combination, a kit and a detection system for evaluating the efficacy of ARB drugs.

Background technique

Hypertension is one of the most common cardiovascular diseases in the world. It often causes complications of the heart, brain, kidney and other organs, seriously endangering human health. According to the 2019 National Survey on Nutrition and Health Status of Residents, the prevalence of hypertension among adults in my country is 18.8%, and there are approximately 160 million patients with hypertension across the country. Our country has become one of the countries with the largest number of patients with hypertension. Because the treatment compliance rate for hypertension is low and it is often combined with multiple risk factors, there is still huge room for improvement in the management and medication of hypertension. Common antihypertensive drugs include five categories: 1. Calcium channel blockers (CCB); 2. Angiotensin-converting enzyme inhibitor (ACEI); 3. Angiotensin II receptors body antagonist (ARB); 4. diuretics; 5. β-blockers.

Among them, angiotensin Ⅱ (Angiotensin Ⅱ, Ang Ⅱ) receptor antagonist (ARB) can inhibit the conversion of Ang Ⅰ into Ang Ⅱ, and can specifically antagonize angiotensin-converting enzyme 1 receptor (AT1), and its antagonistic effect on AT1 is higher than AT2 8500 times, by selectively blocking the binding of Ang II to AT1 receptors, inhibiting vasoconstriction and the release of aldosterone, resulting in antihypertensive effects. Common drugs include losartan, irbesartan, candesartan and telmisartan. The four drugs Losartan, Irbesartan, Candesartan and Telmisartan involve polymorphic sites in many genes, and different types of different genes have different effects on the efficacy, metabolism or absorption of different drugs. are all the same, that is, the efficacy of drug treatment varies between individuals.

Genetic efficacy score (GES) is a drug efficacy evaluation system that establishes an individual's expected benefit from using a certain drug based on genetic polymorphisms. How to use GES for model prediction at the individual level is to identify the possibility of using a specific ARB drug. An effective method to identify potential benefit groups early and select ARB drugs with better efficacy for treatment, which can effectively reduce patients' blood pressure, curb the increase in medical expenses, and extend national life expectancy.

Contents of the invention

It is an object of the present invention to solve at least the above-mentioned problems and to provide at least the advantages to be explained later.

Another object of the present invention is to provide a polymorphic site combination for evaluating the efficacy of ARB drugs, and to provide a kit for evaluating the efficacy of ARB drugs, including identifying each polymorphic site combination in the polymorphic site combination. Primer set for the genetic locus. Further provide a detection system including a kit for evaluating the efficacy of ARB drugs, which can early identify people who benefit from the use of a specific ARB drug and effectively reduce the patient's blood pressure.

In order to achieve these objects and other advantages according to the present invention, a combination of polymorphic sites for evaluating the efficacy of ARB drugs is provided, including:

The polymorphic sites used to evaluate the efficacy of losartan include rs6749447 site, rs10737062 site, rs10752271 site, and rs3814995 site;

Polymorphic sites used to evaluate the efficacy of irbesartan, including the rs1367117 site;

Polymorphic sites used to evaluate the efficacy of telmisartan, including rs5443 site, rs1983023 site, and rs2008584 site;

The polymorphic sites used to evaluate the efficacy of candesartan include the rs1275988 site.

A kit for evaluating the efficacy of ARB drugs, including primer sets 1-9 for identifying each polymorphic site in the polymorphic site combination, wherein:

Primer set 1 for identifying the rs6749447 site consists of the nucleotide sequences shown in SEQ ID No. 1 and SEQ ID No. 2;

Primer set 2 for identifying the rs10737062 site consists of the nucleotide sequences shown in SEQ ID No. 3 and SEQ ID No. 4;

Primer set 3 for identifying the rs10752271 site consists of the nucleotide sequences shown in SEQ ID No. 5 and SEQ ID No. 6;

Primer set 4 for identifying the rs3814995 site consists of the nucleotide sequences shown in SEQ ID No. 7 and SEQ ID No. 8;

Primer set 5 for identifying the rs1367117 site consists of the nucleotide sequences shown in SEQ ID No. 9 and SEQ ID No. 10;

Primer set 6 for identifying the rs5443 site consists of the nucleotide sequences shown in SEQ ID No. 11 and SEQ ID No. 12;

Primer set 7 for identifying the rs1983023 site consists of the nucleotide sequences shown in SEQ ID No. 13 and SEQ ID No. 14;

Primer set 8 for identifying the rs2008584 site consists of the nucleotide sequences shown in SEQ ID No. 15 and SEQ ID No. 16;

Primer set 9 for identifying the rs1275988 site consists of the nucleotide sequences shown in SEQ ID No. 17 and SEQ ID No. 18.

Testing systems for evaluating the efficacy of ARB drugs include:

A kit for detecting the genotype of each polymorphic site carried by the individual to be tested;

A storage unit that stores the weight w of each polymorphic site and the genotype score m of different genotypes of each polymorphic site;

The efficacy score determination unit is connected to the detection unit and the storage unit, and is used to determine the genotype score m of each polymorphic site of the individual to be tested based on the detected genotype, based on the polymorphic site weight w, the detected polymorphism The genotype score m of the locus determines the efficacy score M of the individual to be tested for each drug, In the formula, n is the number of polymorphic sites corresponding to the ARB drug, w _n is the weight of the nth polymorphic site corresponding to the ARB drug, and m _n is the ARB drug. The genotype score measured at the corresponding nth polymorphic site.

Preferably, the weight w of each polymorphic site is:

The weight of the rs6749447 site is 0.85; the weight of the rs10737062 site is 1.07;

The weight of the rs10752271 site is 1.07; the weight of the rs3814995 site is 0.93;

The weight of the rs1367117 site is 0.78; the weight of the rs5443 site is 0.98;

The weight of the rs1983023 site is 0.98; the weight of the rs2008584 site is 1.00;

The weight of rs1275988 site is 0.95.

Preferably, according to the research content in the literature, different genotypes of each polymorphic site are divided into good and poor drug effects and/or fast and slow metabolism, and based on this, the corresponding genotype is given for each genotype. Rating m, specifically:

The risk allele at the rs6749447 locus is G. When the genotypes are GG and GT, m=0; when the genotype is TT, m=1;

The risk allele at the rs10737062 locus is A. When the genotype is AA, m=0; when the genotypes are AG and GG, m=1;

The risk allele of the rs10752271 locus is A. When the genotype is AA, m=0; when the genotypes are AG and GG, m=1;

The risk allele at the rs3814995 locus is C. When the genotype is CC and CT, m=0; when the genotype is TT, m=1;

The risk allele of the rs1367117 locus is A. When the genotype is AA, m=0; when the genotypes are AG and GG, m=1;

The risk allele at the rs5443 locus is T. When the genotype is TT, m=0; when the genotypes are CC and CT, m=1;

The risk allele of the rs1983023 locus is C. When the genotypes are TC and CC, m=0; when the genotype is TT, m=1;

The risk allele at the rs2008584 locus is A. When the genotypes are AG and GG, m=0; when the genotype is AA, m=1;

The risk allele at the rs1275988 locus is T. When the genotype is TT, m=0, and when the genotypes are CC and CT, m=1.

Preferably, the test sample of the individual to be tested is one of the blood, urine, saliva, gastric juice, hair or biopsy of the individual to be tested.

The present invention at least includes the following beneficial effects:

It can simultaneously detect gene polymorphisms at sites related to the efficacy of four ARB drugs for patients with hypertension and give scores, which can be used to comprehensively guide the use of ARB drugs, achieve precise medication, effectively lower the patient's blood pressure, and reduce adverse drug reactions. .

Other advantages, objects, and features of the present invention will be apparent in part from the description below, and in part will be understood by those skilled in the art through study and practice of the present invention.

Detailed ways

The present invention will be further described in detail below with reference to the examples, so that those skilled in the art can implement it according to the text of the description.

1. Obtain 9 polymorphic sites (SNP sites) related to the drug effect (Efficacy) and metabolic rate (Metabolism/PK) of angiotensin II receptor antagonist (ARB) therapeutic drugs through literature and data mining. ), that is, a combination of polymorphic sites for evaluating the efficacy of ARB drugs is obtained, including:

The polymorphic sites used to evaluate the efficacy of losartan include rs6749447 site, rs10737062 site, rs10752271 site, and rs3814995 site;

Polymorphic sites used to evaluate the efficacy of irbesartan, including the rs1367117 site;

Polymorphic sites used to evaluate the efficacy of telmisartan, including rs5443 site, rs1983023 site, and rs2008584 site;

The polymorphic sites used to evaluate the efficacy of candesartan include the rs1275988 site.

2. Based on the combination of polymorphic sites, design corresponding primer sequences. In one specific embodiment, the primer set for evaluating the efficacy of angiotensin II receptor antagonist drugs includes:

Primer set 1, which is used to detect the genetic polymorphism of the rs6749447 site of the STK39 gene, consists of the nucleotide sequences shown in the sequence numbers SEQ ID No. 1 and SEQ ID No. 2;

Amplification upstream primer: GTTTCACTTACGCCCAAGCT (SEQ ID No. 1);

Amplification downstream primer: TGCAGTTAGGTCACCTCCTT (SEQ ID No. 2);

Primer set 2, which is used to detect the genetic polymorphism of the rs10737062 site of the CAMK1D gene, consists of the nucleotide sequences shown in SEQ ID No. 3 and SEQ ID No. 4;

Amplification upstream primer: GCTGGCTGAAACTGGCCTAA (SEQ ID No. 3);

Amplification downstream primer: CTTTCCCAACTGCCCCCAAC (SEQ ID No. 4);

Primer set 3, which is used to detect the genetic polymorphism of the rs10752271 site of the CAMK1D gene, consists of the nucleotide sequences shown in SEQ ID No. 5 and SEQ ID No. 6;

Amplification upstream primer: CTGGTGGAATACCATGGAGCT (SEQ ID No. 5);

Amplification downstream primer: TCTGGATTCCATGCAGCGTT (SEQ ID No. 6);

Primer set 4, which is used to detect the genetic polymorphism of the rs3814995 site of the NPHS1 gene, consists of the nucleotide sequences shown in SEQ ID No. 7 and SEQ ID No. 8;

Amplification upstream primer: GGGCTTGAAGCCCAGACTCA (SEQ ID No. 7);

Amplification downstream primer: CTCCCCTGCAGGTGAATTC (SEQ ID No. 8);

Primer set 5, which is used to detect the genetic polymorphism of the rs1367117 site of the APOB gene, consists of the nucleotide sequences shown in SEQ ID No. 9 and SEQ ID No. 10;

Amplification upstream primer: AGTCACATCCGTGCCTGGTG (SEQ ID No. 9);

Amplification downstream primer: AACCCAGGAGGCATGTTGAT (SEQ ID No. 10);

Primer set 6, which is used to detect the genetic polymorphism of the rs5443 site of the GNB3 gene, consists of the nucleotide sequences shown in SEQ ID No. 11 and SEQ ID No. 12;

Amplification upstream primer: CCCAGGTCTGATCCCTGACC (SEQ ID No. 11);

Amplification downstream primer: CAGTGACAAGGGACAGCAGT (SEQ ID No. 12);

Primer set 7, which is used to detect the genetic polymorphism of the rs1983023 site of the UGT1A3 gene, consists of the nucleotide sequences shown in SEQ ID No. 13 and SEQ ID No. 14;

Amplification upstream primer: GGTGCTGGATTGACTTGGAGA (SEQ ID No. 13);

Amplification downstream primer: TGGAGGCTGGCTATGTGGTT (SEQ ID No. 14);

Primer set 8, which is used to detect the genetic polymorphism of the rs2008584 site of the UGT1A3 gene, consists of the nucleotide sequences shown in SEQ ID No. 15 and SEQ ID No. 16;

Amplification upstream primer: CCCAGTCCTTGGTGAGCAG (SEQ ID No. 15);

Amplification downstream primer: GCACACATGGGCAAGACAACC (SEQ ID No. 16);

Primer set 9, which is used to detect the genetic polymorphism of the rs1275988 site of the KCNK3 gene, consists of the nucleotide sequences shown in SEQ ID No. 17 and SEQ ID No. 18;

Amplification upstream primer: CTGGCTGACTGCCTCCTGAG (SEQ ID No. 17);

Amplification downstream primer: CCCAGCAGAACCGGGATCTA (SEQ ID No. 18);

The above primer set has the advantages of accurate identification, high sensitivity and strong specificity.

3. Kits for evaluating the efficacy of angiotensin II receptor antagonist drugs, including:

Primer sets 1-9 include 10 to 100 pmol of each primer, and other reagents known in the art, such as:

50 μL of 10× amplification buffer;

Each of the four dNTP mixtures is 200 μmol/L;

Template DNA 0.1～2μg;

TaqDNA polymerase 2.5u;

Mg ²⁺ 1.5mmol/L.

4. The detection system for the efficacy of angiotensin II receptor antagonist (ARB) therapeutic drugs, including the following steps:

①. The kit is used to detect the genotype of each polymorphic site carried by the individual to be tested. Detecting the genotype of each polymorphic site carried by the individual to be tested includes the following steps:

1) Obtain the test sample of the individual to be tested, and extract the sample DNA to be tested from the sample to be tested. The specific test sample of the individual to be tested is the blood, urine, saliva, gastric juice, hair or biopsy of the individual to be tested. One type, taking the blood of the individual to be tested as an example:

Obtain the peripheral blood of the individual to be tested and obtain the sample to be tested;

Extract the subject's DNA from the sample to be tested to obtain sample DNA;

2) PCR amplification and purification of sample DNA;

2.1. Mix the PCR reaction solution and add sample DNA to form a reaction system. Perform PCR amplification according to the PCR reaction program to obtain the PCR amplification product. The PCR reaction program is: 94℃/4min; 90-95℃/20s, 50 -60℃/30s, 70-75℃/60s, 45 cycles; keep at 72℃ for 5min; keep at 4℃ until the end of the reaction;

2.2. Use agarose gel electrophoresis to purify the PCR amplification product to obtain the purified PCR amplification product;

3) Sequence the purified PCR amplification product

3.1. Perform a sequencing PCR amplification reaction on the purified PCR amplification product to obtain a sequencing product, including:

The reaction system of sequencing PCR amplification reaction is shown in the following table:

Configure the reaction system: First add water to the 96-well reaction plate. After adding, centrifuge at 1000 rpm to the bottom of the 96-well reaction plate. Then add 2 μL of sequencing primer. After adding, centrifuge at 1000 rpm to the bottom of the 96-well reaction plate. Then Add the purified PCR amplification product, centrifuge it at 1000rpm to the bottom of the 96-well reaction plate, and then add 4ul of diluted Big Dye, where the sequencing primers are the amplification upstream primers corresponding to each polymorphic site;

After adding, attach a sealing film to the reaction plate, press it tightly, and put it into the PCR machine. The reaction parameters are set as: 96°C for 12s, 50°C for 6s, and 60°C for 3min, a total of 24 cycles; 10°C insulation;

3.2. Purify the sequencing product to obtain the purified sequencing product. The purification includes the following steps:

Remove the 96-well reaction plate, centrifuge briefly to 1200rpm, add 1.5 μL of Stop Solution into the centrifuged 96-well reaction plate, and centrifuge briefly to 1200rpm;

Add 100 μL of 75% isopropyl alcohol to the 96-well reaction plate, shake and mix, and let stand in the dark at room temperature for about 10 minutes; after balancing, centrifuge at 4000 rpm, 20°C for 30 minutes;

Turn upside down on absorbent paper and centrifuge instantly to 800rpm. Press the STOP key of the centrifuge;

Add 100 μL of 75% isopropyl alcohol and mix without shaking; after balancing, centrifuge at 4000 rpm, 20°C for 10 min.

Turn upside down on absorbent paper and centrifuge instantly to 800rpm. Press the STOP key of the centrifuge and blow with an electric fan for about 10 minutes in a dark environment to remove residual isopropyl alcohol.

Add 10 μL Hi-Di solution to each well of the reaction plate (10 μL Hi-Di solution must also be added to empty holes), shake to mix, and then centrifuge briefly to 1000 rpm;

3.3. Place the processed 96-well reaction plate in the plastic rack of the computer, cover it with a rubber pad, check whether the 96 wells are aligned, and perform sequencing on the computer to obtain the genotype of each polymorphic site carried by the individual to be tested;

②. Storage unit, which stores the weight w of each polymorphic site and the genotype score m of different genotypes of each polymorphic site. Specifically:

Ⅰ. The weight w of each polymorphic site is shown in Table 1 below:

Table 1 Polymorphic site weight (weight)

Ⅱ. According to the research content in the literature, different genotypes are divided into: good and poor drug effects, fast and slow metabolism, and the corresponding genotype score m is given for each genotype, as shown in Table 2 below:

Table 2 Genotype scores of polymorphic sites

③. The efficacy score determination unit, which is connected to the detection unit and the storage unit, is used to determine the genotype score m of each polymorphic site of the individual to be tested based on the detected genotype, based on the polymorphic site weight w, the number of detected The genotype score m of the genetic locus determines the efficacy score M of the individual to be tested for each drug. In the formula, n is the number of polymorphic sites corresponding to the ARB drug, w _n is the weight of the nth polymorphic site corresponding to the ARB drug, and m _n is the ARB drug. The genotype score measured at the corresponding nth polymorphic site, specifically:

For losartan’s efficacy score M, Among them, m ₁ is the genotype score measured at the rs6749447 site corresponding to losartan; m ₂ is the genotype score measured at the rs10737062 site corresponding to losartan; m ₃ is the genotype score measured at the rs10752271 site corresponding to losartan. The genotype score obtained; m ₄ is the genotype score measured at the rs3814995 locus corresponding to losartan;

For the efficacy score M of irbesartan, M=0.78*m ₁ , where m ₁ is the genotype score measured at the rs1367117 locus corresponding to irbesartan;

For telmisartan’s efficacy score M, Among them, m ₁ is the genotype score measured at the rs5443 site corresponding to telmisartan; m ₂ is the genotype score measured at the rs1983023 site corresponding to telmisartan; m ₃ is the rs2008584 corresponding to telmisartan genotype score measured at the locus;

For the efficacy score M of candesartan, M=0.95*m ₁ , where m ₁ is the genotype score measured at the rs1275988 locus corresponding to candesartan;

4) Determine the ARB drug with the best efficacy score M as the recommended drug.

5. Effect of Medication Guidance

Example 1

Tester No. ZR00080, female, 59 years old, ethnic Han, with a past history of hypertension, diabetes and Helicobacter pylori infection. I came to see a doctor because my blood pressure was not well controlled. I am currently taking 30 mg nifedipine controlled-release tablets qd to control my blood pressure. I complain of leg swelling as a side effect. My blood pressure is currently 140-150mmHg systolic blood pressure (SBP) and 80-90mmHg diastolic blood pressure (DBP). Other oral medications include metformin and pioglitazone for glycemic control, atorvastatin for lipid control, and aspirin and folic acid for antiplatelet therapy.

The patient was genetically tested using the primer set and/or kit of the present invention, and the test results are as shown in the following table:

Test results:

After calculation, losartan scored 0, irbesartan scored 0.78, telmisartan scored 0.99, and candesartan scored 0.95.

According to the genetic testing results, drug efficacy analysis predicted that telmisartan would be more effective, so the treatment plan was modified to telmisartan 80 mg qd. More than one month later, the patient came for a review and reported that his blood pressure SBP was 110-120mmHg and DBP was 70-80mmHg. His blood pressure was well controlled.

Example 2

Tester No. ZR00089, female, 81 years old, ethnic Han, with a past history of hypertension, diabetes and urinary tract stones for 20 years, and no history of drug allergies. In the family history, both father and sister suffer from hypertension. I came to see a doctor because my blood pressure was not well controlled. I am currently taking felodipine extended-release tablets 5 mg qd (taken in the afternoon) and telmisartan 40 mg qd (taken in the morning) to control blood pressure. The current systolic blood pressure (SBP) is 180mmHg and the diastolic blood pressure (DBP) is 60mmHg. Other oral medications include atorvastatin to control blood lipids and Shengmai Yin.

The patient was genetically tested using the primer set and/or kit of the present invention, and the test results are as shown in the following table:

Test results:

The calculated scores were 0.48 for losartan, 0.78 for irbesartan, 0.66 for telmisartan, and 0.95 for candesartan.

According to the genetic test results, it was predicted through pharmacodynamic analysis that candesartan has the best efficacy, followed by irbesartan, followed by telmisartan and losartan. However, since the hospital does not have candesartan, the treatment plan was modified to Irbesartan 150 mg qd, taken at 3-4 pm, plus felodipine extended-release tablet 5 mg qd taken in the morning. More than one month later, the patient came for a review and reported that his blood pressure SBP was 115-135mmHg and DBP was 45-50mmHg. Blood pressure is well controlled.

Although the embodiments of the present invention have been disclosed above, they are not limited to the applications listed in the description and embodiments. They can be applied to various fields suitable for the present invention. For those familiar with the art, they can easily Additional modifications may be made, and the invention is therefore not limited to the specific details and examples shown and described herein without departing from the general concept defined by the claims and equivalent scope.

Claims (3)

1. A kit for evaluating the efficacy of ARB drugs, characterized in that it includes primer sets 1-9 for identifying each polymorphic site in a combination of polymorphic sites for evaluating the efficacy of ARB drugs, The combination of polymorphism sites for evaluating the efficacy of ARB drugs is: The polymorphic sites used to evaluate the efficacy of losartan are rs6749447, rs10737062, rs10752271 and rs3814995; The polymorphic site used to evaluate the efficacy of irbesartan is the rs1367117 site; The polymorphic sites used to evaluate the efficacy of telmisartan are rs5443, rs1983023 and rs2008584; The polymorphic site used to evaluate the efficacy of candesartan is the rs1275988 site; in: Primer set 1 for identifying the rs6749447 site consists of the nucleotide sequences shown in SEQ ID No. 1 and SEQ ID No. 2; Primer set 2 for identifying the rs10737062 site consists of the nucleotide sequences shown in SEQ ID No. 3 and SEQ ID No. 4; Primer set 3 for identifying the rs10752271 site consists of the nucleotide sequences shown in SEQ ID No. 5 and SEQ ID No. 6; Primer set 4 for identifying the rs3814995 site consists of the nucleotide sequences shown in SEQ ID No. 7 and SEQ ID No. 8; Primer set 5 for identifying the rs1367117 site consists of the nucleotide sequences shown in SEQ ID No. 9 and SEQ ID No. 10; Primer set 6 for identifying the rs5443 site consists of the nucleotide sequences shown in SEQ ID No. 11 and SEQ ID No. 12; Primer set 7 for identifying the rs1983023 site consists of the nucleotide sequences shown in SEQ ID No. 13 and SEQ ID No. 14; Primer set 8 for identifying the rs2008584 site consists of the nucleotide sequences shown in SEQ ID No. 15 and SEQ ID No. 16; Primer set 9 for identifying the rs1275988 site consists of the nucleotide sequences shown in SEQ ID No. 17 and SEQ ID No. 18. 2. A detection system for evaluating the efficacy of ARB drugs, which is characterized by including: The kit according to claim 1, used to detect the genotype of each polymorphic site carried by the individual to be tested; A storage unit that stores the weight w of each polymorphic site and the genotype score m of different genotypes of each polymorphic site; The efficacy score determination unit is connected to the detection unit and the storage unit, and is used to determine the genotype score m of each polymorphic site of the individual to be tested based on the detected genotype, based on the polymorphic site weight w, the detected polymorphism The genotype score m of the locus determines the efficacy score M of the individual to be tested for each drug, M= , in the formula, n is the number of polymorphic sites corresponding to the ARB drug, w _n is the weight of the nth polymorphic site corresponding to the ARB drug, m _n is the ARB class The genotype score measured at the nth polymorphic site corresponding to the drug; The weight w of each polymorphic site is: The weight of the rs6749447 site is 0.85; the weight of the rs10737062 site is 1.07; the weight of the rs10752271 site is 1.07; the weight of the rs3814995 site is 0.93; the weight of the rs1367117 site is 0.78; the weight of the rs5443 site is 0.98; rs1983023 Bit The weight of the point is 0.98; the weight of the rs2008584 point is 1.00; the weight of the rs1275988 point is 0.95; According to the research content in the literature, different genotypes of each polymorphic site are divided into good and poor drug effects and/or fast and slow metabolic rates, and based on this, a corresponding genotype score m is given for each genotype. Specifically, for: The risk allele at the rs6749447 locus is G. When the genotypes are GG and GT, m=0; when the genotype is TT, m=1; The risk allele at the rs10737062 locus is A. When the genotype is AA, m=0; when the genotypes are AG and GG, m=1; The risk allele of the rs10752271 locus is A. When the genotype is AA, m=0, and when the genotypes are AG and GG, m=1; The risk allele at the rs3814995 locus is C. When the genotypes are CC and CT, m=0; when the genotype is TT, m=1; The risk allele of the rs1367117 locus is A. When the genotype is AA, m=0; when the genotypes are AG and GG, m=1; The risk allele at the rs5443 locus is T. When the genotype is TT, m=0, and when the genotypes are CC and CT, m=1; The risk allele of the rs1983023 locus is C. When the genotype is TC and CC, m=0; when the genotype is TT, m=1; The risk allele of the rs2008584 locus is A. When the genotypes are AG and GG, m=0. When the genotype is AA, m=1; The risk allele at the rs1275988 locus is T. When the genotype is TT, m=0, and when the genotypes are CC and CT, m=1. 3. The detection system for evaluating the efficacy of ARB drugs according to claim 2, wherein the sample to be tested of the individual to be tested is one of blood, urine, saliva, gastric juice, hair or biopsy of the individual to be tested. kind.